Home > Oncology > ASCO 2021 > Breast Cancer > Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine

Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine

Presented By
Prof. Ingrid Mayer, Vanderbilt University School of Medicine, TN, USA
Conference
ASCO 2021
Trial
Phase 3, ECOG-ACRIN EA1131
In the ECOG-ACRIN EA1131 trial, platinum-based adjuvant chemotherapy in patients with (basal subtype) triple-negative breast cancer (TNBC) with residual invasive disease did not prove to be non-inferior or superior to capecitabine adjuvant chemotherapy. The trial was discontinued after the fifth interim analysis. Patients with TNBC who have residual invasive disease after completion of neoadjuvant chemotherapy have a very high risk of recurrence [1]. Recently, the CREATE-X trial showed this risk is reduced by adjuvant capecitabine, while pre-clinical models suggest TNBC basal subtype has increased sensitivity for platinum-based chemotherapy [2,3]. Therefore, the randomised, phase 3 ECOG-ACRIN EA1131 trial (NCT0244539) tested the hypothesis that invasive disease-free survival would be improved in patients with basal subt...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on